Myopathy and rhabdomyolysis with lipid-lowering drugs

Toxicology Letters

Volumn 128, Issue 1-3, 2002, Pages 159-168

  Hodel, Christian ^a  

^a Hovat Pharma Consulting   (Switzerland)

Author keywords

Fibrates; Hyperlipidemic; Myopathy; Rhabdomyolysis; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; CREATINE KINASE; CYCLOSPORIN; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; MIBEFRADIL; NICOTINAMIDE; PRAVASTATIN; SIMVASTATIN;

ARTICLE; DEATH; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG USE; ENZYME INDUCTION; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; MONOTHERAPY; MORTALITY; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ANIMALS; ANTILIPEMIC AGENTS; CLOFIBRATE; FEMALE; HUMANS; LOVASTATIN; MALE; MIDDLE AGED; MUSCULAR DISEASES; RHABDOMYOLYSIS;

ANIMALIA;

EID: 0037051164     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(02)00010-3     Document Type: Article

References (68)

1. Clofibrate-induced myotoxicity in rats. Temporal profile of myopathology
2. Simvastatin
3. Lovastatin and rhabdomyolysis
4. Rhabdomyolysis under treatment with ciprofibrate during a nephrotic syndrome
5. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
6. Stereospecificity of the chloride ion channel: The action of chiral clofibric acid analogues
7. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives
8. Fènofibrate: Études de toxicologie animale en rapport avec les effets secondaires chez les malades
9. Toxic myopathy due to hypolipemic agents
10. Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia
11. Syndrome musculaire atypique avec myolyse au cours d'un traitement chronique par fibrates
12. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels
13. An investigation into the role of the skeletal muscle as a site for xenobiotic metabolism using microsomes and isolated cells
14. Rhabdomyolyse aiguë au cours d'un traitement par le ciprofibrate
15. Malignant hyperthermia
16. Clofibrate, nephrotic syndrome, and histological changes in muscle
17. Creatinine rise after fibrate therapy in renal graft recipients
18. Judicious evaluation of adverse drug reactions: Inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury
19. Acute-on-chronic renal failure precipitated by clofibrate
20. Clofibrate-induced myotonia in the rat
21. Hyperkalemia during treatment with HMG-CoA reductase inhibitor
22. Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers
23. Adam (MDMA) and Eve (MDEA) misuse: An immunohistochemical study on three fatal cases
24. Rhabdomyolyse avec insuffisance rénale aiguë: Rôle de l'association fibrate et hypothyroïde
25. Medikamentös und toxisch-induzierte muskelnekrose
26. Myopathy as possible side-effect of cyclosporin
27. L'hypothyroïdie potentialise-t-elle la toxicité musculaire des fibrates
28. Nebenwirkungen der lipidsenker
29. Simvastatin und pravastatin: Erfahrungen der SANZ mit diesen neuen lipidsenkern aus der reihe der cholesterol-syntheses-enzymhemmer
30. Rhabdomyolysis with acute renal failure due to bezafibrate
31. Risk profile of lipid-lowering drugs
32. Muscular syndrome after clofibrate
33. Delayed toxic reaction following massive bee envenomation
34. Myotoxicity in lipid-lowering therapy
35. Myotonia induced with clofibrate in rats
36. Acute muscular syndrome associated with administration of clofibrate
37. Atteintes musculaires et fibrates
38. Drug-induced myopathies
39. Salicylate induced rhabdomyolysis
40. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
41. Extended clinical safety profile of lovastatin
42. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy
43. Drug-induced disorders of muscle
44. Adverse effects of drugs on muscle
45. Adverse reactions to fibric acid derivatives in Spain
46. Muskelschwäche als leit-oder warnsymptom unter medikamentöser therapie und bei intoxikationen
47. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin
48. Rhabdomyolysis and HMG-CoA reductase inhibitors
49. Miconazole-ciprofibrate interaction causing rhabdmomyolysis. Case report
50. Mode of inhibition of mitochondrial energy transduction by chlorophenoxyisobutyrate
51. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
52. Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle
53. Survival after massive ecstasy overdose
54. Lovastatin, nicotinic acid and rhabdomyolysis
55. Alcohol-associated rhabdomyolysis: Ethanol induction of cytochrome P450 may potentiate myotoxcity
56. Clofibrate-induced muscular syndrome. Case report with ultrastructural findings and review of the literature
57. Bezafibrat-induzierte myolyse und myoglobinurie bei patienten mit eingeschränkter nierenfunktion
58. Clofibrate myopathy: A case report and a review of the literature
59. Schwere rhabdomyolysis nach opiatintoxikation
60. Tolerability of fibric acids. Comparative data and biochemical bases
61. HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies
62. Rhabdomyolyse (Oorzaken)
63. Clofibrate-induced myopathy in the rat
64. Effects of exercise and lovastatin on serum creatine kinase activity
65. Does hypothyroidism predispose towards fibrate-induced muscle toxicity
66. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs
67. Myositis, hypothyroidism and fibrates
68. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins